On May 26, 2020, the U.S. Food and Drug Administration (“FDA” or “Agency”) issued an immediately in effect guidance, Recommendations for Sponsors Requesting EUAs for Decontamination and Bioburden ...
As biopharma companies fine-tune their strategies for continuous bioprocessing, bioburden control has become a top priority. The approaches that worked for batch processing are inadequate for ...
The Global Bioburden Testing Market has experienced consistent growth, with a compound annual growth rate (CAGR) of 12-15%. This growth is driven by tightening regulatory standards and an increasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results